1.
2.
3.
4.
5.
6.
7.
8.
9.
Di, X.P.; Luo, D.Y.; Jin, X.; Zhao, W.Y.; Li, H.; Wang, K.J. Efficacy and safety comparison of pharmacotherapies for interstitial
cystitis and bladder pain syndrome: A systematic review and Bayesian network meta-analysis. Int. Urogynecol. J. 2021, 32,
1129–1141. [CrossRef] [PubMed]
Yoshimura, N.; Homma, Y.; Tomoe, H.; Otsuka, A.; Kitta, T.; Masumori, N.; Akiyama, Y.; Niimi, A.; Mitsui, T.; Nanri, M.; et al.
Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution) for interstitial cystitis/bladder pain
syndrome in Japanese patients: A multicenter, randomized, double-blind, placebo-controlled, clinical study. Int. J. Urol. 2021, 28,
545–553. [CrossRef] [PubMed]
Homma, Y.; Akiyama, Y.; Tomoe, H.; Furuta, A.; Ueda, T.; Maeda, D.; Lin, A.T.; Kuo, H.C.; Lee, M.H.; Oh, S.J.; et al. Clinical
guidelines for interstitial cystitis/bladder pain syndrome. Int. J. Urol. 2020, 27, 578–589. [CrossRef] [PubMed]
Hanno, P.M.; Erickson, D.; Moldwin, R.; Faraday, M.M. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome:
AUA guideline amendment. J. Urol. 2015, 193, 1545–1553. [CrossRef] [PubMed]
Hillelsohn, J.H.; Rais-Bahrami, S.; Friedlander, J.I.; Okhunov, Z.; Kashan, M.; Rosen, L.; Moldwin, R.M. Fulguration for Hunner
ulcers: Long-term clinical outcomes. J. Urol. 2012, 188, 2238–2241. [CrossRef]
Ryu, J.; Pak, S.; Song, M.; Chun, J.Y.; Hong, S.; Choo, M.S. Elimination of Hunner’s Ulcers by Fulguration in Patients With
Interstitial Cystitis: Is It Effective and Long Lasting? Korean J. Urol. 2013, 54, 767–771. [CrossRef]
Kajiwara, M.; Inoue, S.; Kobayashi, K.; Ohara, S.; Teishima, J.; Matsubara, A. Therapeutic efficacy of narrow band imaging-assisted
transurethral electrocoagulation for ulcer-type interstitial cystitis/painful bladder syndrome. Int. J. Urol. 2014, 21 (Suppl. 1),
57–60. [CrossRef]
Chennamsetty, A.; Khourdaji, I.; Goike, J.; Killinger, K.A.; Girdler, B.; Peters, K.M. Electrosurgical management of Hunner ulcers
in a referral center’s interstitial cystitis population. Urology 2015, 85, 74–78. [CrossRef]
Glemain, P.; Rivière, C.; Lenormand, L.; Karam, G.; Bouchot, O.; Buzelin, J.M. Prolonged hydrodistention of the bladder for
symptomatic treatment of interstitial cystitis: Efficacy at 6 months and 1 year. Eur. Urol. 2002, 41, 79–84. [CrossRef]
Int. J. Mol. Sci. 2022, 23, 5037
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
12 of 14
El-Hefnawy, A.S.; Makharita, M.Y.; Abed, A.; Amr, Y.M.; Salah El-Badry, M.; Shaaban, A.A. Anesthetic Bladder Hydrodistention
Is Superior to Superior Hypogastric Plexus Neurolysis in Treatment of Interstitial Cystitis-bladder Pain Syndrome: A Prospective
Randomized Trial. Urology 2015, 85, 1039–1044. [CrossRef]
Niimi, A.; Nomiya, A.; Yamada, Y.; Suzuki, M.; Fujimura, T.; Fukuhara, H.; Kume, H.; Igawa, Y.; Homma, Y. Hydrodistension
with or without fulguration of hunner lesions for interstitial cystitis: Long-term outcomes and prognostic predictors. Neurourol.
Urodyn. 2016, 35, 965–969. [CrossRef] [PubMed]
Hoke, T.P.; Goldstein, H.; Saks, E.K.; Vakili, B. Hydrodistention of the bladder for the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC). Neurourol. Urodyn. 2017, 36, 784–786. [CrossRef] [PubMed]
Kirk, P.S.; Santiago-Lastra, Y.; Qin, Y.; Stoffel, J.T.; Clemens, J.Q.; Cameron, A.P. The effects of cystoscopy and hydrodistention on
symptoms and bladder capacity in interstitial cystitis/bladder pain syndrome. Neurourol. Urodyn. 2018, 37, 2002–2007. [CrossRef]
[PubMed]
Abelleyra Lastoria, D.A.; Raison, N.; Aydin, A.; Khan, S.; Dasgupta, P.; Ahmed, K. Comparing surgical interventions for interstitial
cystitis: A systematic review. Low Urin. Tract. Symptoms 2022. [CrossRef]
Jiang, Y.H.; Jhang, J.F.; Lee, Y.K.; Kuo, H.C. Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for
Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment.
Biomedicines 2022, 10, 396. [CrossRef]
Evans, M.; Judy, W.V.; Wilson, D.; Rumberger, J.A.; Guthrie, N. Randomized, double-blind, placebo-controlled, clinical study on
the effect of Diabetinol((R)) on glycemic control of subjects with impaired fasting glucose. Diabetes Metab. Syndr. Obes. 2015, 8,
275–286. [CrossRef]
Gandhi, G.R.; Vasconcelos, A.B.S.; Wu, D.T.; Li, H.B.; Antony, P.J.; Li, H.; Geng, F.; Gurgel, R.Q.; Narain, N.; Gan, R.Y. Citrus
Flavonoids as Promising Phytochemicals Targeting Diabetes and Related Complications: A Systematic Review of In Vitro and In
Vivo Studies. Nutrients 2020, 12, 907. [CrossRef]
Jang, S.E.; Ryu, K.R.; Park, S.H.; Chung, S.; Teruya, Y.; Han, M.J.; Woo, J.T.; Kim, D.H. Nobiletin and tangeretin ameliorate scratching behavior in mice by inhibiting the action of histamine and the activation of NF-kappaB, AP-1 and p38. Int. Immunopharmacol.
2013, 17, 502–507. [CrossRef]
Lee, Y.S.; Cha, B.Y.; Saito, K.; Yamakawa, H.; Choi, S.S.; Yamaguchi, K.; Yonezawa, T.; Teruya, T.; Nagai, K.; Woo, J.T. Nobiletin
improves hyperglycemia and insulin resistance in obese diabetic ob/ob mice. Biochem. Pharmacol. 2010, 79, 1674–1683. [CrossRef]
Matsuzaki, K.; Ohizumi, Y. Beneficial Effects of Citrus-Derived Polymethoxylated Flavones for Central Nervous System Disorders.
Nutrients 2021, 13, 145. [CrossRef]
Singh, B.; Singh, J.P.; Kaur, A.; Singh, N. Phenolic composition, antioxidant potential and health benefits of citrus peel. Food Res.
Int. 2020, 132, 109114. [CrossRef] [PubMed]
Boucher, M.; Meen, M.; Codron, J.P.; Coudore, F.; Kemeny, J.L.; Eschalier, A. Cyclophosphamide-induced cystitis in freely-moving
conscious rats: Behavioral approach to a new model of visceral pain. J. Urol. 2000, 164, 203–208. [CrossRef]
Chuang, Y.C.; Yoshimura, N.; Huang, C.C.; Chiang, P.H.; Chancellor, M.B. Intravesical botulinum toxin a administration produces
analgesia against acetic acid induced bladder pain responses in rats. J. Urol. 2004, 172, 1529–1532. [CrossRef] [PubMed]
Boudes, M.; Uvin, P.; Kerselaers, S.; Vennekens, R.; Voets, T.; De Ridder, D. Functional characterization of a chronic
cyclophosphamide-induced overactive bladder model in mice. Neurourol. Urodyn. 2011, 30, 1659–1665. [CrossRef]
Auge, C.; Chene, G.; Dubourdeau, M.; Desoubzdanne, D.; Corman, B.; Palea, S.; Lluel, P.; Vergnolle, N.; Coelho, A.M. Relevance
of the cyclophosphamide-induced cystitis model for pharmacological studies targeting inflammation and pain of the bladder.
Eur. J. Pharmacol. 2013, 707, 32–40. [CrossRef]
Homan, T.; Tsuzuki, T.; Dogishi, K.; Shirakawa, H.; Oyama, T.; Nakagawa, T.; Kaneko, S. Novel mouse model of chronic
inflammatory and overactive bladder by a single intravesical injection of hydrogen peroxide. J. Pharmacol. Sci. 2013, 121, 327–337.
[CrossRef]
Birder, L.; Andersson, K.E. Animal Modelling of Interstitial Cystitis/Bladder Pain Syndrome. Int. Neurourol. J. 2018, 22, S3–s9.
[CrossRef]
Okinami, T.; Imamura, M.; Nishikawa, N.; Negoro, H.; Sugino, Y.; Yoshimura, K.; Kanematsu, A.; Hashitani, H.; Ogawa, O. Altered
detrusor gap junction communications induce storage symptoms in bladder inflammation: A mouse cyclophosphamide-induced
model of cystitis. PLoS ONE 2014, 9, e104216. [CrossRef]
Cajas, Y.N.; Cañón-Beltrán, K.; Ladrón de Guevara, M.; Millán de la Blanca, M.G.; Ramos-Ibeas, P.; Gutiérrez-Adán, A.; Rizos, D.;
González, E.M. Antioxidant Nobiletin Enhances Oocyte Maturation and Subsequent Embryo Development and Quality. Int. J.
Mol. Sci. 2020, 21, 5340. [CrossRef]
Kono, J.; Ueda, M.; Sengiku, A.; Suadicani, S.O.; Ogawa, O.; Negoro, H. Urothelium-Specific Deletion of Connexin 43 in the
Mouse Urinary Bladder Alters Distension-Induced ATP Release and Voiding Behavior. Int. J. Mol. Sci. 2021, 22, 1594. [CrossRef]
Negoro, H.; Kanematsu, A.; Doi, M.; Suadicani, S.O.; Matsuo, M.; Imamura, M.; Okinami, T.; Nishikawa, N.; Oura, T.; Matsui, S.;
et al. Involvement of urinary bladder Connexin 43 and the circadian clock in coordination of diurnal micturition rhythm. Nat.
Commun. 2012, 3, 809. [CrossRef] [PubMed]
Sengiku, A.; Ueda, M.; Kono, J.; Sano, T.; Nishikawa, N.; Kunisue, S.; Tsujihana, K.; Liou, L.S.; Kanematsu, A.; Shimba, S.;
et al. Circadian coordination of ATP release in the urothelium via connexin43 hemichannels. Sci. Rep. 2018, 8, 1996. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2022, 23, 5037
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
13 of 14
Birder, L.A.; Kullmann, F.A. Role of neurogenic inflammation in local communication in the visceral mucosa. Semin. Immunopathol.
2018, 40, 261–279. [CrossRef]
Birder, L.A. Urinary bladder, cystitis and nerve/urothelial interactions. Auton. Neurosci. 2014, 182, 89–94. [CrossRef]
Negoro, H.; Urban-Maldonado, M.; Liou, L.S.; Spray, D.C.; Thi, M.M.; Suadicani, S.O. Pannexin 1 channels play essential roles in
urothelial mechanotransduction and intercellular signaling. PLoS ONE 2014, 9, e106269. [CrossRef]
Li, W.; Wang, X.; Niu, X.; Zhang, H.; He, Z.; Wang, Y.; Zhi, W.; Liu, F. Protective Effects of Nobiletin Against Endotoxic Shock in
Mice Through Inhibiting TNF-α, IL-6, and HMGB1 and Regulating NF-κB Pathway. Inflammation 2016, 39, 786–797. [CrossRef]
[PubMed]
Lin, Z.; Wu, D.; Huang, L.; Jiang, C.; Pan, T.; Kang, X.; Pan, J. Nobiletin Inhibits IL-1β-Induced Inflammation in Chondrocytes via
Suppression of NF-κB Signaling and Attenuates Osteoarthritis in Mice. Front. Pharmacol. 2019, 10, 570. [CrossRef] [PubMed]
Wang, H.; Guo, Y.; Qiao, Y.; Zhang, J.; Jiang, P. Nobiletin Ameliorates NLRP3 Inflammasome-Mediated Inflammation Through
Promoting Autophagy via the AMPK Pathway. Mol. Neurobiol. 2020, 57, 5056–5068. [CrossRef]
Shao, B.Z.; Xu, Z.Q.; Han, B.Z.; Su, D.F.; Liu, C. NLRP3 inflammasome and its inhibitors: A review. Front. Pharmacol. 2015, 6, 262.
[CrossRef]
Zheng, D.; Liwinski, T.; Elinav, E. Inflammasome activation and regulation: Toward a better understanding of complex mechanisms. Cell Discov. 2020, 6, 36. [CrossRef]
Chen, L.; Wang, H.; Ge, S.; Tai, S. IL-6/STAT3 pathway is involved in the regulation of autophagy in chronic non-bacterial
prostatitis cells, and may be affected by the NLRP3 inflammasome. Ultrastruct. Pathol. 2021, 45, 297–306. [CrossRef] [PubMed]
Lu, J.; Su, Y.; Chen, X.; Chen, Y.; Luo, P.; Lin, F.; Zhang, J. Rapamycin-induced autophagy attenuates hormone-imbalance-induced
chronic non-bacterial prostatitis in rats via the inhibition of NLRP3 inflammasome-mediated inflammation. Mol. Med. Rep. 2019,
19, 221–230. [CrossRef] [PubMed]
Hughes, F.M., Jr.; Hill, H.M.; Wood, C.M.; Edmondson, A.T.; Dumas, A.; Foo, W.C.; Oelsen, J.M.; Rac, G.; Purves, J.T. The
NLRP3 Inflammasome Mediates Inflammation Produced by Bladder Outlet Obstruction. J. Urol. 2016, 195, 1598–1605. [CrossRef]
[PubMed]
Hughes, F.M., Jr.; Hirshman, N.A.; Inouye, B.M.; Jin, H.; Stanton, E.W.; Yun, C.E.; Davis, L.G.; Routh, J.C.; Purves, J.T. NLRP3
Promotes Diabetic Bladder Dysfunction and Changes in Symptom-Specific Bladder Innervation. Diabetes 2019, 68, 430–440.
[CrossRef]
Hughes, F.M., Jr.; Sexton, S.J.; Jin, H.; Govada, V.; Purves, J.T. Bladder fibrosis during outlet obstruction is triggered through the
NLRP3 inflammasome and the production of IL-1β. Am. J. Physiol. Renal. Physiol. 2017, 313, F603–F610. [CrossRef]
Lütolf, R.; Hughes, F.M., Jr.; Inouye, B.M.; Jin, H.; McMains, J.C.; Pak, E.S.; Hannan, J.L.; Purves, J.T. NLRP3/IL-1β mediates
denervation during bladder outlet obstruction in rats. Neurourol. Urodyn. 2018, 37, 952–959. [CrossRef]
Hughes, F.M., Jr.; Vivar, N.P.; Kennis, J.G.; Pratt-Thomas, J.D.; Lowe, D.W.; Shaner, B.E.; Nietert, P.J.; Spruill, L.S.; Purves, J.T.
Inflammasomes are important mediators of cyclophosphamide-induced bladder inflammation. Am. J. Physiol. Renal. Physiol.
2014, 306, F299–F308. [CrossRef]
Chen, L.; He, P.L.; Yang, J.; Yang, Y.F.; Wang, K.; Amend, B.; Stenzl, A.; Zhang, Y.M.; Wang, Z.L.; Xing, S.S.; et al. NLRP3/IL1beta
inflammasome associated with the aging bladder triggers bladder dysfunction in female rats. Mol. Med. Rep. 2019, 19, 2960–2968.
[CrossRef]
Verma, V.; Gupta, S.; Kumar, P.; Yadav, S.; Dhanda, R.S.; Gaind, R.; Arora, R.; Frimodt-Moller, N.; Yadav, M. Involvement of
NLRP3 and NLRC4 Inflammasome in Uropathogenic E. coli Mediated Urinary Tract Infections. Front. Microbiol. 2019, 10, 2020.
[CrossRef]
Shih, H.J.; Chang, C.Y.; Lai, C.H.; Huang, C.J. Therapeutic effect of modulating the NLRP3-regulated transforming growth
factor-beta signaling pathway on interstitial cystitis/bladder pain syndrome. Biomed. Pharmacother. 2021, 138, 111522. [CrossRef]
Korkmaz, A.; Topal, T.; Oter, S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis;
implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol. Toxicol. 2007, 23, 303–312. [CrossRef]
[PubMed]
Malley, S.E.; Vizzard, M.A. Changes in urinary bladder cytokine mRNA and protein after cyclophosphamide-induced cystitis.
Physiol. Genomics 2002, 9, 5–13. [CrossRef] [PubMed]
Wong, P.; Laxton, V.; Srivastava, S.; Chan, Y.W.; Tse, G. The role of gap junctions in inflammatory and neoplastic disorders
(Review). Int. J. Mol. Med. 2017, 39, 498–506. [CrossRef] [PubMed]
Cliff, C.L.; Williams, B.M.; Chadjichristos, C.E.; Mouritzen, U.; Squires, P.E.; Hills, C.E. Connexin 43: A Target for the Treatment of
Inflammation in Secondary Complications of the Kidney and Eye in Diabetes. Int. J. Mol. Sci. 2022, 23, 600. [CrossRef]
Swartzendruber, J.A.; Nicholson, B.J.; Murthy, A.K. The Role of Connexin 43 in Lung Disease. Life 2020, 10, 363. [CrossRef]
Zhang, X.; Yao, J.; Gao, K.; Chi, Y.; Mitsui, T.; Ihara, T.; Sawada, N.; Kamiyama, M.; Fan, J.; Takeda, M. AMPK Suppresses
Connexin 43 Expression in the Bladder and Ameliorates Voiding Dysfunction in Cyclophosphamide-induced Mouse Cystitis. Sci.
Rep. 2016, 6, 19708. [CrossRef]
Willebrords, J.; Crespo Yanguas, S.; Maes, M.; Decrock, E.; Wang, N.; Leybaert, L.; Kwak, B.R.; Green, C.R.; Cogliati, B.; Vinken, M.
Connexins and their channels in inflammation. Crit. Rev. Biochem. Mol. Biol. 2016, 51, 413–439. [CrossRef]
Peng, B.; Xu, C.; Wang, S.; Zhang, Y.; Li, W. The Role of Connexin Hemichannels in Inflammatory Diseases. Biology 2022, 11, 237.
[CrossRef]
Int. J. Mol. Sci. 2022, 23, 5037
59.
60.
61.
62.
63.
64.
65.
14 of 14
Final report on the safety assessment of Glycyrrhetinic Acid, Potassium Glycyrrhetinate, Disodium Succinoyl Glycyrrhetinate,
Glyceryl Glycyrrhetinate, Glycyrrhetinyl Stearate, Stearyl Glycyrrhetinate, Glycyrrhizic Acid, Ammonium Glycyrrhizate, Dipotassium Glycyrrhizate, Disodium Glycyrrhizate, Trisodium Glycyrrhizate, Methyl Glycyrrhizate, and Potassium Glycyrrhizinate.
Int. J. Toxicol. 2007, 26 (Suppl. 2), 79–112. [CrossRef]
Deutch, M.R.; Grimm, D.; Wehland, M.; Infanger, M.; Krüger, M. Bioactive Candy: Effects of Licorice on the Cardiovascular
System. Foods 2019, 8, 495. [CrossRef]
Roza, J.M.; Xian-Liu, Z.; Guthrie, N. Effect of citrus flavonoids and tocotrienols on serum cholesterol levels in hypercholesterolemic
subjects. Altern. Ther. Health Med. 2007, 13, 44–48. [PubMed]
Yamada, S.; Shirai, M.; Ono, K.; Teruya, T.; Yamano, A.; Tae Woo, J. Beneficial effects of a nobiletin-rich formulated supplement
of Sikwasa (C. depressa) peel on cognitive function in elderly Japanese subjects; A multicenter, randomized, double-blind,
placebo-controlled study. Food Sci. Nutr. 2021, 9, 6844–6853. [CrossRef] [PubMed]
Schuchardt, J.P.; Heine, S.; Hahn, A. A combination of palm oil tocotrienols and citrus peel polymethoxylated flavones does
not influence elevated LDL cholesterol and high-sensitivity C-reactive protein levels. Eur. J. Clin. Nutr. 2015, 69, 1209–1214.
[CrossRef] [PubMed]
Kim, J.; Ji, M.; DiDonato, J.A.; Rackley, R.R.; Kuang, M.; Sadhukhan, P.C.; Mauney, J.R.; Keay, S.K.; Freeman, M.R.; Liou, L.S.; et al.
An hTERT-immortalized human urothelial cell line that responds to anti-proliferative factor. In Vitro Cell Dev. Biol. Anim. 2011, 47,
2–9. [CrossRef] [PubMed]
el-Fouly, M.H.; Trosko, J.E.; Chang, C.C. Scrape-loading and dye transfer. A rapid and simple technique to study gap junctional
intercellular communication. Exp. Cell Res. 1987, 168, 422–430. [CrossRef]
...
論文の公開元へ
